84 ANTI-AGEING A
120 100 80 60 40 20 0
Beta galactosidase activity
Statistics: Mean ± SEM n=16 Student t test vs P11 untreated control
(*) p<0.05 (***) p<0.001
B (*) -24% (***)
120 100 80 60 40 20 0
P5
Untreated control
P11
Untreated control
P11
Lysimachia extract at 0.05%
p16 protein expression
Statistics: Mean ± SEM n=12 Student t test vs P11 untreated control
(**) p<0.01 (***) p<0.001
-34% (**)
(***)
P5
Untreated control
P11
Untreated control
P11
Lysimachia extract at 0.05%
Figure 1: Evaluation of beta galactosidase activity (A) and p16 protein expression (B) at early (P5) and late (P11) stage of replication, and after addition of Lysimachia extract
associated secretory phenotype, thereby minimizing inflammation and protecting the surrounding tissue. Antioxidants play a crucial role by neutralizing reactive oxygen species, reducing oxidative stress, and delaying the onset of senescence, ultimately supporting the maintenance of youthful and resilient skin.
Lysimachia christinae: A natural- based solution for longevity Oximony™, a new product developed by BASF's Personal Care business, has been shown to effectively combat cellular senescence. The ingredient is an extract of Lysimachia christinae, a perennial herb from the Primulaceae family. In traditional Chinese medicine (TCM), the plant is widely used for its detoxifying properties and wound-healing effects. The fast-growing climbing vine is native to parts of Asia, particularly China. It thrives in humid and subtropical regions, and is often found on sloping hillsides, wetlands, forest edges, and shaded areas. The new product (INCI: Maltodextrin (and)
Lysimachia Christinae Flower/Leaf/Stem Extract, hereafter called Lysimachia extract) is derived from the aerial parts of the plant using an extraction process that utilizes water as the sole solvent. It is characterized by polyphenols and classified as 100% from natural origin according to the ISO 16128 standard. Additionally, the Lysimachia extract is
certified according to the FairWild standard, which guarantees the preservation of both the harvested plant and its surrounding ecosystem. The FairWild certification process is based on seven principles and 24 criteria, addressing ecological sustainability, socio-cultural respect, and business requirements for sustainable wild collection.
Demonstrated efficacy on skin longevity in vitro The ability of this new bioactive to promote skin longevity was evaluated both in vitro and in vivo. In vitro, the properties of the extract were
PERSONAL CARE April 2025
demonstrated on the reduction in cellular senescence by decreasing the number of senescent cells in a replicative senescence model, and by decreasing SASP production and secretion in a stress-induced senescence model. In vivo, a placebo-controlled clinical study
was conducted to evaluate the effects of the new product at 0.25% on the reduction of skin fatigue and increased firmness of facial skin.
Senescence delay The effects on cellular senescence were studied in a model that mimics replicative senescence using human fibroblasts and allowing them to enter senescence by subculturing for several passages. Cells exhibiting characteristics of young cells were referred to as P5 (the fifth passage corresponding to the untreated control). Replicative senescent fibroblast cells were
induced by prolonged passage P11 (the eleventh passage) in cell culture. At each stage, beta- galactosidase activity, the primary biomarker of senescence, was measured. An increase in this enzymatic activity indicates an increase in senescent
cells. Levels of p16 protein, another marker of senescence, were also measured. The p16 protein inhibits cyclin-dependent
kinases (CDKs) required for cell cycle progression, effectively contributing to cell cycle arrest. Elevated levels of p16 are a hallmark of senescence, as this prevents cells from dividing. Beta-galactosidase activity was detected by staining, while p16 was evaluated by Western blot analysis. The accumulation of senescent cells is
known to affect skin function and regenerative capacity. As part of the study, the ability of the new product to inhibit cellular senescence in fibroblasts was evaluated by measuring beta-galactosidase activity and p16 protein expression (Figure 1). At the P5 stage, minimal beta-galactosidase
activity was observed, indicating a low level of cellular senescence. However, by P11, untreated cells showed a significant increase in beta- galactosidase activity, reflecting a marked increase in the number of senescent cells. In contrast, cells treated with the Lysimachia extract throughout the culture process showed
Lysimachia christinae
www.personalcaremagazine.com
% of β galactosidase activity
% of p16
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
